Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 15/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429705 | 0.89 | PDK2 (0.44) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL974511 | 0.89 | PDK2 (0.44) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL20434891 | 0.83 | PDK2 (0.42) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL22071263 | 0.81 | PDK2 (0.46) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL29506891 | 0.80 | MEN1 (0.52) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL816912 | 0.80 | MEN1 (0.52) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL194556 | 0.77 | PDK2 (0.54) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL30211372 | 0.77 | PDK2 (0.54) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL29351148 | 0.77 | PDK2 (0.54) | PDK2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL17050236 | 0.77 | PDK2 (0.54) | PDK2MEN1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696878-B2 | Fluorene derivative, method for producing the same, resin composition, and article | DEXERIALS CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-20180215969-A1 | Fluorene Derivative, Method for Producing the Same, Resin Composition, and Article | KINKI UNIVERSITY (JP) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215969-A1 | Fluorene Derivative, Method for Producing the Same, Resin Composition, and Article | FRG1, F12, FXR1 | PDK2 4552/4885MEN1 2336/4885MAPT 3882/4885 |
| US-10696878-B2 | Fluorene derivative, method for producing the same, resin composition, and article | FRG1, F12, FXR1 | PDK2 4552/4885MEN1 2336/4885MAPT 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.